New hope for PNH patients who still struggle with anemia despite current treatments

This Phase 3 trial tested whether HRS-5965 capsules could help patients with paroxysmal nocturnal hemoglobinuria (PNH) who continue to have anemia despite already receiving standard C5 inhibitor treatments like eulizumab. The study involved 39 adults who took the capsules for 24 weeks while researchers measured improvements in hemoglobin levels and reduced need for blood transfusions. This approach aims to provide better disease control for patients who don't respond fully to existing therapies.